Research Continues for Best Immunotherapy Order in Advanced RCC

Even with the increase of immunotherapy utilization to treat patients with advanced renal cell carcinoma, more research is needed to determine in which order to administer it as later lines of therapy.

Related Keywords

New York ,United States ,Dorothy Byrne ,Robertj Motzer ,Lenvima Welireg ,Genitourinary Oncology Service ,Kidney Cancer Research Summit ,National Comprehensive Cancer Network ,Kidney Cancer ,Dorothy Byrne Chair ,Clinical Oncology ,Memorial Sloan Kettering Cancer Center ,Cancer Research Summit ,Comprehensive Cancer Network ,Cancers Symposium ,